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Abstract: Reactive oxygen species (ROS) are wieldy accepted as one of the main factors 
of the aging process. These highly reactive compounds modify nucleic acids, proteins and 
lipids and affect the functionality of mitochondria in the first case and ultimately of the 
cell. Any agent or genetic modification that affects ROS production and detoxification can 
be expected to influence longevity. On the other hand, genetic manipulations leading to 
increased  longevity  can  be  expected  to  involve  cellular  changes  that  affect  ROS 
metabolism.  The  66-kDa  isoform  of  the  growth  factor  adaptor  Shc  (p66Shc)  has  been 
recognized as a relevant factor to the oxygen radical theory of aging. The most recent data 
indicate that p66Shc protein regulates life span in mammals and its phosphorylation on 
serine 36 is important for the initiation of cell death upon oxidative stress. Moreover, there 
is strong evidence that apart from aging, p66Shc may be implicated in many oxidative 
stress-associated  pathologies,  such  as  diabetes,  mitochondrial  and  neurodegenerative 
disorders and tumorigenesis. This article summarizes recent knowledge about the role of 
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p66Shc in aging and senescence and how this protein can influence ROS production and 
detoxification, focusing on studies performed on skin and skin fibroblasts. 
Keywords: p66Shc; reactive oxygen species; antioxidant defense; mitochondria 
 
1. Introduction 
A broad body of evidence describes the tissue-specific thresholds of reactive oxygen species (ROS) 
which,  if  surpassed,  exert  oxidative  stress.  Harman’s  free  radical  theory  of  aging,  proposes  that  
an  uncontrolled  increase  of  ROS  results  in  oxidative  damage  of  fundamental  cellular  components  
such as proteins, phospholipids and DNA [1]. Accumulation of such damages has a negative impact  
on  the  functions  of  tissues  and  organs,  leading  to  aging  and  various  pathologies.  Both,  oxidative  
and  genetic-related  defects  of  the  mitochondrial  respiratory  chain,  age-dependent  decrease  of  the 
antioxidant defense system efficiency, as well as the activity of certain proteins (such as p66Shc), 
make  a  relevant  contribution  to  enhanced  intracellular  ROS  production.  Investigation  of  these 
mechanisms,  especially  the  pivotal  properties  of  p66Shc,  permits  a  better  understanding  of  aging. 
Here, we attempt to systematize the existing knowledge governing the activity of p66Shc in processes 
of aging and the emergence of various pathologies associated with oxidative stress.  
2. Age-Related Dysfunctions of the Mitochondrial Respiratory Chain and Antioxidant Defense 
Several  lines  of  evidence  indicate  that  in  different  tissues  the  activity  of  some  mitochondrial 
respiratory complexes declines with age. In rodents the age-dependent decrease in electron transfer 
chain  (ETC)  activity  in  a  variety  of  tissues  (e.g.,  brain,  kidney,  heart  and  liver)  refers  mainly  to 
complexes I and IV of the respiratory chain. Complex II and III remain practically unaffected during 
aging  [2–7].  In  1994  Boffoli  et  al.  [2]  demonstrated  that  a  decrease  in  the  activity  of  particular 
respiratory  chain  complexes  can  be  correlated with  the  reduction  of  their  content  in  mitochondria  
as  illustrated in Figure 1. This phenomenon was confirmed by a  number of authors (reviewed  by  
Van Remmen et al. [8]).  
Generation  of  ROS  due  to  leakage  of  electrons  from  the  ETC  is  an  inherent  characteristic  of 
mitochondrial respiration. ROS, in accordance to Harman’s free radical theory of aging, are the main 
contributor in this process [1]. An inhibition of the respiration rate and corresponding higher reduction 
of the respiratory chain components, due to decreased respiratory chain complexes content elevates 
electron  leakage  and  ROS  formation.  In  accordance  with  the  above  mentioned  observations, 
mitochondrial ATP synthesis has been reported to decrease with age in different human tissues [9,10] 
and skin fibroblasts [11]. 
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Figure 1. Age-dependent changes in the expression of respiratory chain subunits in mouse 
skin.  Expression  profile  of  respiratory  chain  subunits  in  skin  from  1-month-old  and  
10-month-old  mouse;  St.—standard  (mitochondria  isolated  from  mouse  heart);  
HSP60-marker  of  mitochondrial  content  in  the  sample.  Antibodies  and  experimental 
protocols were as previously described [12,13]. 
 
In a study on primary human fibroblasts derived from subjects of different age groups ranging from 
20 weeks fetal to 103 years, Greco et al. characterized several mitochondrial processes underlying the 
capacity  of  oxidative  phosphorylation  (OXPHOS)  during  aging.  The  following  mitochondrial 
parameters were monitored: mitochondrial protein synthesis, the respiratory rate and a coupling of the 
oxydative phosphorylation. The authors observed a very significant reduction in the ratio of uncoupled 
to oligomycin inhibited endogenous respiration in aged fibroblasts which pointed to a decrease with 
donor’s age in the control of respiration by the mitochondrial membrane potential. The authors also 
describe a decrease in the respiratory control ratio with the subject’s age. Greco and co-workers also 
underlined the plausibility of a hypothesis  in which ROS play a key role  in such deterioration  by 
affecting both mtDNA and nDNA and finally leading to insufficient mitochondrial protein levels as 
well  as  mitochondrial  lipid  peroxidation  [11].  Age-dependent  alterations  also  affect  mitochondrial 
morphology.  Mitochondria  in  cells  of  aged  individuals  (e.g.,  mice)  have  altered  intracellular 
organization and increased volume as illustrated in Figure 2 [14]. Int. J. Mol. Sci. 2011, 12                       
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Figure  2.  Age-dependent  changes  in  mitochondrial  structure  of  mice  fibroblasts.  
(A) Mitochondrial structure (a), actin filaments (b) and microtubules (c) organization in 
fibroblasts from 1-day-old (1 d) mice; and (B) Age-dependent changes in mitochondrial 
structure of mice fibroblasts from 1-day-old (1 d), 6-month-old (6 m) and 18-month-old 
(18 m) mice. Mitochondrial structure, actin filaments and microtubules organization was 
visualized as previously described [15]. 
 
2.1. Antioxidant Defense and Aging 
Though the intracellular free radical production brings a potent danger to the cell, contributing to 
various pathologies and aging process, cells defend themselves with the multifactorial antioxidative 
system which includes scavenging enzymes and compounds. In the mitochondrial matrix, manganese 
superoxide dismutase (MnSOD or SOD2) converts the superoxide anion to hydrogen peroxide, which 
is then detoxified in the cytosol by catalase to water molecule. The mitochondrial matrix also contains 
glutathione peroxidise (GPX) and two peroxiredoxins (Prx 3 and 5) that eliminate hydrogen peroxide 
(H2O2). The mitochondrial intermembrane space and the cytosol contain the zinc-copper superoxide 
dismutase  (Zn-Cu  SOD  or  SOD1)  whose  activation  depends  on  the  intracellular  redox  state  [16].  
An important role in redox homeostasis is played by the glutathione system. The GSH/GSSG balance 
is kept by glutathione metabolism enzymes: glutathione peroxidise and glutathione reductase. They 
both are responsible for keeping the proper balance between oxidized and reduced forms of gluthatione 
and correspondingly they control the redox level within the cell. Furthermore, they control the level of 
ROS [17]. It was documented by many investigators that antioxidant enzyme levels change with age. 
Their decrease together with the increase in ROS level might be harmful to proteins, phospholipids  
and mtDNA [18].  
Cell susceptibility to oxidative damage depends on the antioxidant defense efficiency. Thus in cases 
of aberrant scavenging ability,  cells are  more prone to premature aging and carcinogenesis due to 
oxidative  DNA  damage.  Many  animal  models  with  antioxidant  enzyme  deficiencies  show  higher 
susceptibility to prooxidant factors such as toxic agents and radiation [19]. On the other hand, boosting Int. J. Mol. Sci. 2011, 12                       
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antioxidant defense system can potentially prevent pathological changes and may delay aging. For 
example in case of long-living Ames dwarf mice, dermal fibroblasts are resistant to mitochondrially 
generated ROS due to upregulation of stress responding cascades [20]. During maturation and aging 
cells lose their ability to defend against ROS. These characteristics are also manifested in cell cultures 
in the late passages, and are referred to as proliferative senescence. It is caused by an accumulation of 
peroxidation products, decrease of non-enzymatic antioxidants, e.g., Coenzyme Q10, and decline in 
antioxidant  enzymes  efficiency.  There  is  a  significant  loss  of  mitochondrial  function  in  aging, 
represented by lower mitochondrial membrane potential, higher superoxide production by the electron 
transfer chain accompanied by lower ATP production and a more frequent appearance of oxidized 
proteins. CoQ10 administration to the human skin not only seems to reduce visible age-associated 
changes  but  prevents  DNA  oxidation  which  was  suggested  to  protect  against  aging  and  prevent 
carcinogenesis [21]. Cells that are particularly exposed to external stress factors are skin fibroblasts. 
UV radiation (UVA and UVB) seems to be very harmful for them inducing free radical production, 
which leads to senescence as well as dermatological complications. Such enhanced skin aging process 
(as a consequence to UV exposure) is called photoaging [22,23].  
2.2. Antioxidant Supplementation 
It has been indicated by many studies that supplementation of cell culture media with antioxidants 
improves mitochondrial metabolism and other cell functions by decreasing oxidative stress. Various 
mechanisms have been suggested to underlie such benefits, from simple radical reduction to inducing 
complex signal cascades responsible for antioxidant defense and repair. Antioxidant supplementation 
may be particularly important in cases of age-associated loss of antioxidant capacity. Cells growing in 
the  presence  of  compounds  possessing  antioxidant  capacity,  such  as  vitamin  E,  display  prolonged 
proliferative lifespan and reduced senescence [24,25]. Effective protection against photoaging can be 
provided by vitamin C and E supplementation. Since dietary intake of these compounds may be not 
sufficient, additional topical vitamin C application from cosmetics maintains its high level in dermal 
fibroblasts resulting in DNA protection and an increase in collagen synthesis [24,25]. Aging fibroblasts 
are  characterized  by  the  decline  in  respiratory  function  and  partial  uncoupling.  Such  defects  in 
oxidative phosphorylation result in insufficient energy supply which affects the proliferative potential 
of a cell [26]. In such a case, ascorbate supplementation of human fibroblasts can restore enzymatic 
function of the mitochondrial respiratory chain complexes which results in a delay of aging associated 
with mitochondrial dysfunction [27]. Nowadays, a number of natural compounds from the group of 
polyphenols and isoflavones are being tested as antioxidants. Some of them, apart from scavenging 
reactive oxygen species, also improve antioxidant defense, mitochondrial energy metabolism and retard 
aging  process  [28].  For  example  even  short  incubation  (24  h)  with  the  Epigallocatechin-3-gallate 
(EGCG), from green tea extract, increases expression of main antioxidant enzymes (catalase, SOD1, 
SOD2 and glutathione peroxidase). Longer treatment results in significant decrease of intracellular 
oxidative stress and higher DNA protection [29]. Sesamol, a polyphenolic compound, which is a very 
potent agent against UVB-induced oxidative stress in dermal fibroblasts, represents similar characteristics. 
It not only increases antioxidant enzyme levels but also decreases the level of lipid peroxides which 
are markers of cell damage during aging process [30]. Recent studies with antioxidants mitoQ and SkQ Int. J. Mol. Sci. 2011, 12                       
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which  are  targeting  specifically  mitochondria  seems  promising  [31].  SkQ  works  in  very  low 
concentrations, efficiently preventing mitochondrial cardiolipin oxidation and H2O2-induced apoptosis 
in  cultured  human  fibroblasts.  Moreover  SkQ  treatment  decreases  the  occurrence  of  spontaneous 
apoptosis in fibroblasts from old individuals to the level observed in cells from young animals [31]. 
p66Shc  is  a  protein  that  partially  participates  in  above  described  age  (and  ROS)-dependent 
mitochondrial  dysfunctions  and  cellular  pathologies.  Its  involvement  in  the  cellular  response  to 
oxidative  stress,  resulting  in  higher/additional  ROS  production  by  mitochondria  and  the  ability  to 
influence the intracellular level of antioxidant enzymes was demonstrated in primary cultures of mouse 
skin  fibroblasts  [32,33]  as  well  as  in  fibroblasts  derived  from  patients  harboring  different 
mitochondrial dysfunctions [12].  
3. p66Shc—The Oxidative Stress and Longevity 
In 1999 the group of Pelicci [33] published an observation pointing to the role of p66Shc protein in 
oxidative stress and aging. The authors proposed that the mammalian life span can be controlled by the 
p66Shc protein and  importantly, this effect is due to the regulation of the cellular response to the 
oxidative stress. These intriguing studies on the transgenic mice lacking p66Shc showed that mice that 
lack the gene appear to have a 30% increase in life span (compared to mice with a wild type phenotype) 
without  pathological  consequences  such  as  increase  of  tumor  frequency  and  endocrinological 
abnormalities.  Studies  of  Tomilov  et  al.  [34]  showed  that  decreased  superoxide  production  in 
macrophages of p66Shc
−/− mice may result in a lower inflammation status and can protect animals 
from oxidative injury. Taken together these results partly explain the phenomena of the longevity of 
the  p66Shc  lacking  mice  [34].  However,  the  lack  of  p66Shc  (which  is  a  negative  regulator  of 
p46Shc/p52Shc-mediated Ras signaling) results also in an enhancement of lymphocyte proliferation 
and of immune responses to the antigen exposure. These changes can correspond to development of 
autoimmune diseases in p66Shc knock-out mice [35].  
4. p66Shc—One Protein Two Functions 
The p66Shc protein is a growth factor adaptor protein which together with p52Shc and p46Shc 
belongs  to  the  ShcA  family.  All  ShcA  proteins  have  similar  domain  structure  and  contain  three 
functionally identical domains: the carboxy terminal Src homology 2 (SH2) domain, central proline-rich 
domain (CH1), and the N-terminal phosphotyrosine-binding domain (PTB). The structure and function 
of the individual domains has been extensively described in [36]. p66Shc differs from p56Shc and 
p46Shc by the presence of an additional N-terminal proline-rich collagen-homology domain (CH2), 
which contains a serine phosphorylation site (Ser36) important for the “proapoptotic” properties of 
p66Shc [36,37]. Moreover, p66Shc contains a functional region (CCB) responsible for interaction with 
cytochrome  c  [38].  Under  physiological  condition  p66Shc  is  involved  in  the  signal  transduction 
(modulation) from, e.g., epidermal growth factor (EGF) receptor to the nucleus. When phosphorylated 
at tyrosine  residues,  p52Shc  and  p46Shc  have  been  found  to  bind  to the  Grb2/SOS  complex—an 
activator of the Ras protein. p66Shc can be phosphorylated at tyrosine and it can also interact with 
Grb2, but there is no evidence that in this way it can activate the Ras signaling pathway. Therefore, 
p66Shc competes with p52Shc to bind Grb2, which suggests that p66Shc can be a dominant negative Int. J. Mol. Sci. 2011, 12                       
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regulator of the Ras-mediated signaling pathway [39]. Under oxidative stress (UV exposure or H2O2 
treatment) Ser36 of the p66Shc protein is phosphorylated by one the serine-threonine kinases, protein 
kinase Cβ (PKCβ), which triggers the signaling pathway leading to apoptosis. This cascade of events 
has been described by us [32] and consists of four important steps. Briefly: Step 1—in response to the 
oxidative stress p66Shc is phosphorylated at Ser36. Step 2—phosphorylated p66Shc is isomerised by a 
prolyl isomerase Pin1. Step 3—isomerised, phosphorylated at Ser36 p66Shc is dephosphorylated by 
phosphatase A2 (PP2A). Step 4—dephosphorylated p66Shc is finally translocated to the mitochondria 
where it participates in ROS production [38]. 
It is still unclear whether p66Shc  is translocated across the outer mitochondrial  membrane and 
resides in the mitochondrial intermembrane space where it can interact with cytochrome c [38] or  
it  binds  to  the  outer  mitochondrial  membrane  from  the  cytosolic  side.  Recently,  our  group  
discovered  that  p66Shc  is  also  present  in  plasma  membrane-associated  membrane  (PAM)  and  in 
mitochondria-associated  membrane  (MAM)  fractions  [13,40,41]  and  that  the  level  of  p66Shc  in  
these fractions changes in an age-dependent manner. MAM fraction isolated from livers of old animals 
contained more p66Shc than MAM isolated from 1-month-old mice. Moreover, increased levels of 
p66Shc  in  crude  liver  mitochondria  (containing  MAM)  of  old  mice,  correlated  positively  with 
enhanced H2O2 production measured in mitochondrial preparation [13]. However, regardless of the 
fact of how p66Shc interacts/enters mitochondria, it appears to modulate mitochondrial metabolism 
and participate in ROS production [42]. 
5. A New Job for p66Shc: Its Role in Adipocyte Metabolism 
The deletion of p66Shc has been found to protect mice from a number of degenerative diseases 
based  on  cell  loss  [43].  Moreover,  the  effect  of  p66Shc  deficiency  on  atherogenesis  has  been  
studied, especially after challenge with a high fat diet, in mice [44]. Major decreases of atherogenesis 
were  observed  in  p66Shc
−/−  mice  vs.  controls  fed  a  high-fat  diet,  and  reduced  expression  of  
oxidation-specific epitopes was observed in their arterial walls, and reduced vascular apoptosis was 
observed. Furthermore, plasma isoprostanes (a marker of lipid oxidative damage) were decreased both 
in unchallenged and fat-challenged p66Shc
−/− mice [44]. 
Apart from this pathological function of p66Shc, this protein also functions in the regulation of 
insulin signaling and adipocyte metabolism [45]. In fat cells, p66Shc potentiates insulin signaling and 
triglyceride accumulation. Genetic experiments showed that this effect of p66Shc is mediated by its 
phosphorylation (on serine-36 phosphorylation) and its ability to generate ROS. Notably, the PTEN 
phosphatase inhibits insulin signaling and is inactivated by oxidation, suggesting that it may function 
as  one  of  the  targets  of  p66Shc-generated  ROS.  Thus,  p66Shc-generated  ROS  might  be  critical 
regulators of insulin signaling and fat development. Remarkably, p66Shc
−/− mice are protected from 
diet-induced obesity, suggesting that p66Shc regulates diet-associated fat development [45,46]. 
Furthermore, p66Shc
−/− mice have reduced body weight, due to reduced fat mass of both white and 
brown  adipose  tissues  [45].  This  leanness  is  not  explainable  by  changes  in  food  intake,  intestinal 
absorption  of  nutrients  or  locomotor  activity.  Rather,  it  may  reflect  defects  in  lipogenesis  of 
adipocytes, as suggested by the reduced lipid accumulation of p66Shc
−/− adipocytes transplanted into 
WT recipient mice [45]. However, this interpretation of the mechanisms leading to decreased fat mass Int. J. Mol. Sci. 2011, 12                       
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in p66Shc
−/− mice poses the question of how energy balance is maintained in the absence of p66Shc, 
and why energy storage is reduced. As p66Shc
−/− mice showed increased basal body temperature and 
increased  basal  metabolic  rate  [45],  this  suggests  that  increased  uncoupled  respiration  in  the  fat 
mitochondria of p66Shc
−/− mice leads to increased energy expenditure, which contributes to resistance 
to body weight gain. Moreover, Ranieri and colleagues showed that p66 deficiency protects against fat 
accumulation and premature death in lepOb/Ob mice, an established genetic model of obesity and 
insulin resistance [46].  
However, this lean and resistant to diet-induced obesity phenotype of p66Shc
−/− mice cannot be 
solely the result of p66Shc deletion. Indeed, it has been recently demonstrated as p66Shc
−/− mice in 
addition to p66Shc deletion have a fourfold increase in p46Shc expression in white fat. Thus, p46Shc 
overexpression in fat, rather than p66Shc deletion, could be the likely cause of decreased adiposity and 
reduced insulin sensitivity in the fat of p66Shc
−/− mice [47]. 
6. Studies on p66Shc in Fibroblast Models 
Studies performed on fibroblasts derived from mice lacking p66Shc also demonstrated an increased 
resistance to oxidative stress [32,33] and lower basal ROS production [33]. In contrast to wild type 
cells, treatment with H2O2 of p66Shc knock-out fibroblasts did not affect mitochondrial structure and 
calcium  uptake  [32].  Accordingly,  accumulation  of  carbonylated  proteins  in  p66Shc
−/−  fibroblasts 
(indicating the scale of the oxidative damage of proteins) was  significantly  lower as compared  to  
wild type cells. The phenomenon of enhanced resistance to oxidative stress of p66Shc
−/− fibroblasts 
was intensively studied by Nemoto and Finkiel [48]. Based on their data, it can be concluded that  
Ser36-P-p66Shc  additionally  acts  as  a  negative  regulator  of  antioxidant  enzyme  synthesis.  FoxO 
proteins are known to be involved  in the  modulation of energy  metabolism,  proliferation and cell 
death. FoxO transcription factors can also regulate the level of SOD2 and catalase. Ser36-P-p66Shc 
acts negatively on FoxO which results in decreased amounts of both enzymes. Interplay between the 
proapoptotic protein p53 and phosphorylated p66Shc which inhibits FOXO3a transcriptional activity 
resulting in decreased level of catalase and SOD2 has been recently described by Pani et al. [49]. 
Apparently, cells lacking p66Shc are more resistant to apoptotic stimuli like H2O2.  
In our recent paper we have shown that the level of the Ser36-P-p66Shc is positively correlated 
with the age of a mouse (in older animals the phosphorylation status of p66Shc is higher) that may 
partially  explain  higher  superoxide  and  H2O2  production  observed  in  old  animals  [13,50,51].  For 
example in the skin of adult mice there is more p66Shc and Ser36-P-p66Shc comparing to the material 
obtained from 1 day old individuals [13]. Interestingly, levels of p66Shc in fibroblasts derived from 18 
months  old,  6  months  old  and  one  day  old  mice  are  similar.  This  result  is  in  variance  with  the 
observation  of  Pandolfi  and  colleagues  that  p66Shc  is  highly  expressed  in  fibroblasts  from 
centenarians [52]. The expression ration between Ser36-P-p66Shc to Actin (1 d = 1.75; 6 m = 1.81;  
18 m = 1.89) showed increasing phosphorylation of p66Shc, indicating that the p66Shc pathway was 
activated.  Similarly,  the  level  of  p66Shc  in  neonatal  human  dermal  fibroblasts  (NHDF-Neonatal,  
Cat. n. CC-2509, Lonza) and adult human dermal fibroblasts (NHDF-Adult, Cat. n. CC-2511, Lonza) 
seems to be expressed at the same level. Both cytosolic and mitochondrial superoxide production in 
adult fibroblasts have been found increased (see Figure 3), which together with the observed lower Int. J. Mol. Sci. 2011, 12                       
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level of SOD 2 (as we described in [13]) can indicate the existence of higher oxidative stress in cells 
from older individuals. 
Figure  3. Superoxide production  in human dermal  fibroblasts. Cytosolic (cytO2
●−) and 
mitochondrial  (mtO2
● −)  superoxide  production  in  neonatal  human  dermal  fibroblasts 
(NHDF-Neonatal,  Cat.  n.  CC-2509,  Lonza)  (Fm)  and  adult  human  dermal  fibroblasts 
(NHDF-Adult,  Cat.  n.  CC-2511,  Lonza)  (Fd).  Superoxide  production  was  measured  as 
previously described in [12]. 
 
However, NAD/NADH redox state has been found comparable in both cell lines [53]. Decreased 
level  of  SOD2  is  in  an  agreement  with  data  already  published  [54–56]  that  with  age  antioxidant 
defense  is  less  efficient  due  to  decreased  activity  of  antioxidant  enzymes  like  GPX  1,  GR  and 
mitochondrial SOD2.  
More straightforward evidence for the participation of the p66Shc protein in mitochondrial function 
came from replicative senescence as a model of aging. The consequences of excess oxidative stress, 
caused in part by the altered function of oxidative phosphorylation in replicative senescent human 
fibroblasts, have been studied by the group of Wei [57–59]. These authors proposed that age-related 
oxidative stress leads to an increased expression and activation of some nuclear genes that are involved 
in mitochondrial biogenesis leading in effect to an increase in mitochondrial mass and mtDNA copy 
number. Such a response to oxidative stress plays a dual role. First, it can increase the supply of energy 
necessary for such processes as DNA repair and protein synthesis, necessary for cell survival under 
stress conditions. On the other hand, by further increase in ROS production it can lead to an elevation 
of oxidative stress and propel the vicious cycle leading to cell aging or death [57–59]. In this model the 
levels of  both p66Shc and Ser36-P-p66Shc significantly  increase  from passage to passage  but the 
Ser36-P-p66Shc rises even with a faster kinetics. The calculated phosphorylation status of p66Shc 
(ratio  Ser36-P-p66Shc  to  p66Shc)  indicates  that  more  p66Shc  is  phosphorylated  at  late  passages  
(see Figure 4). 
During  aging/senescence,  lower  efficiency  of  the  antioxidant  defense  system  and  gradually 
accumulated  mitochondrial  and  nuclear  DNA  damages  are  the  main  causes  of  an  increase  of 
intracellular ROS level. This activates PKCβ-dependent phosphorylation of p66Shc which finally not 
only perturbs mitochondrial structure but also affects their function, e.g., by modifying mitochondrial 
Ca
2+ responses [32,42]. Int. J. Mol. Sci. 2011, 12                       
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Figure 4. Passage-dependent changes of Shc proteins and Ser36-phosphorylated p66Shc in 
mouse  fibroblasts.  Actin  was  used  as  loading  control.  Antibodies  and  experimental 
protocols were as previously described in [12]. 
 
7. Mitochondrial Ca
2+ Homeostasis is Compromised in Senescent Cells through a p66Shc 
Dependent Pathway 
The electrical gradient across the inner membrane (~180 mV) represents a strong thermodynamic 
force in favor of the accumulation of cations like Ca
2+ [60]. Mitochondrial Ca
2+ homeostasis has been 
shown to regulate diverse cellular functions such as cellular ATP production, proliferation, and cell 
death  [61,62].  The  processes  involved  in  mitochondrial  calcium  homeostasis  are  schematically 
presented in Figure 5(A).  
Figure  5.  Calcium  homeostasis  in  p66Shc  wt  and  p66Shc
−/−  cells.  (A)  Mitochondria-
endo/sarcopalsmic  reticulum  (ER/SR)  Ca
2+  crosstalk.  MCU—calcium  uniporter,  
NCX—Na
+/Ca
2+  exchanger;  (B)  Peak  in  mitochondrial  Ca
2+  responses  after  agonist 
stimulation in wt and p66Shc knockout MEFs (ko) at different passage number. [Ca
2+]m 
was measured using the aequorin wt probe as previously described [32]. 
 Int. J. Mol. Sci. 2011, 12                       
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Stimulation of plasma membrane receptors coupled to a Gq protein causes opening of Ca
2+ channels 
of the ER membrane (IP3R), and the release of Ca
2+ from the ER into the cytoplasm. In healthy cells, 
the inner mitochondrial membrane is nearly impermeable to ions with an exception of Ca
2+ which 
transport  across  the  inner  mitochondrial  membrane  depends  on  the  activity  of  the  electrogenic 
“uniporter” (MCU) of  low affinity. Inhibition of the respiratory chain or collapse of the electrical 
gradient (e.g., by the use of a protonophore) abolishes the capacity of mitochondria to accumulate 
Ca
2+. The specific zones of close contact between ER and mitochondria cause that mitochondria are 
exposed to microdomains of high [Ca
2+] that largely exceed the values reported in the bulk cytosol and 
meet the low affinity of the uniporter [63].  
In primary cell cultures, such as the mouse embryonic fibroblasts (MEFs) the [Ca
2+]m responses 
after agonist stimulation, gradually decreased with time in culture (and thus with the passage number) 
whereas no alteration was observed in p66Shc
−/− MEFs (see Figure 5(B)) [32]. Moreover, inhibition  
of  p66Shc  phosphorylation  with  the  use  of  hispidin,  an  inhibitor  of  PKC,also  abolished  
passage-dependent  decrease  of  mitochondrial  calcium  uptake  in  wild  type  fibroblasts  [32].  These 
observations  clearly  link  the  progressive  mitochondrial  damage  (and  the  associated  reduced 
mitochondrial responsiveness) observed during the senescence process to the involvement of the ROS 
sensor p66Shc.  
8. p66Shc Pathway Is Activated by Intracellular Oxidative Stress—Studies on Fibroblasts from 
Patients Harboring Mitochondrial Defects 
Additional pieces of evidence for the participation of the p66Shc protein in mitochondrial ROS 
production came  from studies using fibroblasts derived from patients harboring mitochondrial defects 
[12]. Such skin fibroblasts are regularly used in diagnostics as an alternative to muscle biopsy because 
they can  be easily collected (even post mortem), cultured and stored [64–67]. On the other hand, 
carrying  out  mitochondrial  diagnostics  and  studies  performed  in  cultured  fibroblasts  have  serious 
limitations. First, mitochondrial DNA mutations exhibit varying degrees of heteroplasmy, and may be 
eliminated in the subsequent culture passages. Moreover, certain mtDNA mutations affecting protein 
synthesis (tRNA mutations) are quickly eliminated from the culture, whereas mutations of the genes of 
structural subunits, e.g., of complex I (ND1-6) can “survive” in culture. However, it seems that many 
of the mitochondrial diseases with Mendelian inheritance can be detected and studied in fibroblasts. 
This  is  particularly  important  in  children  where  mutations  in  nuclear  genes  predominate  in 
mitochondrial pathologies and can consist up to 80% of all cases. For this reason  in our recently 
published  studies,  we  used  fibroblasts  derived  from  patients  with  various  mitochondrial  disorders 
(mitochondrial DNA mutations in ND3 subunit and tRNA leucine, TAZ gene mutation, MEGDEL 
association) [12]. 
The signaling pathway involving p66Shc phosphorylation described earlier refers to the situation in 
which oxidative stress is  induced, e.g., by H2O2 addition to the fibroblasts culture. In such a case 
p66Shc phosphorylation on Ser36 is caused by extracellular oxidative stress. Our recent studies showed 
that also intracellular oxidative stress (of mitochondrial origin) activates p66Shc phosphorylation on 
Ser36. In the case of patients’ fibroblasts (mitochondrial dysfunction results in significantly increased 
intracellular  oxidative  stress)  phosphorylation  of  p66Shc  on  Ser36  was  significantly  increased. Int. J. Mol. Sci. 2011, 12                       
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Moreover, we found a substantially decreased level of SOD2 in these cells what additionally confirmed 
the observation that SOD2 is under control of the p66Shc Ser36 phosphorylation status [12].  
9. Concluding Remarks 
Former studies  indicate that, disregarding the source of the oxidative stress, phosphorylation of 
p66Shc on Ser36 affects mitochondrial metabolism and induces mitochondrial ROS production. This 
consequently increases intracellular oxidative stress and initiates a vicious circle of p66Shc-dependent 
ROS  production.  Completely  understanding  the  role  of  p66Shc  protein  in  cell  physiology  and 
pathology will require further extensive studies that in the future will permit a better understanding of 
the  mechanisms  governing  processes  like  aging  and  various  pathologies  associated  with  oxidative 
stress.  Additionally,  the  assessment  of  p66Shc  phosphorylation  changes  in  mitochondrial  patients’ 
fibroblasts  may  represent  a  very  promising  approach  to  study  to  what  extent  the  endogenous  ROS 
overproduction contributes to tissue damage in various genetic mitochondrial defects of known, and 
especially of unknown, molecular origin. Prospective future therapies of mitochondrial disorders may 
also be tested by this method. 
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